Jason Bednar
Stock Analyst at Piper Sandler
(2.15)
# 2,844
Out of 5,182 analysts
202
Total ratings
37.75%
Success rate
-5%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRTS Alpha Tau Medical | Downgrades: Neutral | $5 | $6.83 | -26.79% | 6 | Mar 4, 2026 | |
| ICUI ICU Medical | Maintains: Overweight | $172 → $178 | $122.99 | +44.73% | 4 | Feb 20, 2026 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $113 → $106 | $67.81 | +56.32% | 15 | Feb 18, 2026 | |
| BDX Becton, Dickinson and Company | Reiterates: Neutral | $205 → $170 | $155.32 | +9.45% | 13 | Feb 10, 2026 | |
| NVST Envista Holdings | Reiterates: Neutral | $21 → $25 | $25.81 | -3.14% | 15 | Feb 6, 2026 | |
| ALGN Align Technology | Maintains: Overweight | $200 → $220 | $171.87 | +28.00% | 33 | Feb 5, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Overweight | $91 → $94 | $70.40 | +33.52% | 2 | Jan 30, 2026 | |
| MDLN Medline | Initiates: Overweight | $50 | $43.88 | +13.95% | 1 | Jan 12, 2026 | |
| SHC Sotera Health Company | Upgrades: Overweight | $17 → $24 | $14.87 | +61.40% | 4 | Jan 9, 2026 | |
| COO The Cooper Companies | Reiterates: Overweight | $83 → $94 | $70.29 | +33.73% | 15 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $94 → $98 | $63.25 | +54.94% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $4 | $4.26 | -6.10% | 8 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $210 | $178.49 | +17.65% | 16 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $2.5 | $1.36 | +83.82% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $10.55 | +222.27% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $11.64 | +37.46% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $74.86 | +2.86% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $3.46 | +30.06% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $219.97 | +20.47% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $2.05 | +192.68% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $0.71 | +2,720.87% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $452.58 | -17.80% | 4 | Jan 3, 2024 |
Alpha Tau Medical
Mar 4, 2026
Downgrades: Neutral
Price Target: $5
Current: $6.83
Upside: -26.79%
ICU Medical
Feb 20, 2026
Maintains: Overweight
Price Target: $172 → $178
Current: $122.99
Upside: +44.73%
Merit Medical Systems
Feb 18, 2026
Maintains: Overweight
Price Target: $113 → $106
Current: $67.81
Upside: +56.32%
Becton, Dickinson and Company
Feb 10, 2026
Reiterates: Neutral
Price Target: $205 → $170
Current: $155.32
Upside: +9.45%
Envista Holdings
Feb 6, 2026
Reiterates: Neutral
Price Target: $21 → $25
Current: $25.81
Upside: -3.14%
Align Technology
Feb 5, 2026
Maintains: Overweight
Price Target: $200 → $220
Current: $171.87
Upside: +28.00%
GE HealthCare Technologies
Jan 30, 2026
Maintains: Overweight
Price Target: $91 → $94
Current: $70.40
Upside: +33.52%
Medline
Jan 12, 2026
Initiates: Overweight
Price Target: $50
Current: $43.88
Upside: +13.95%
Sotera Health Company
Jan 9, 2026
Upgrades: Overweight
Price Target: $17 → $24
Current: $14.87
Upside: +61.40%
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $70.29
Upside: +33.73%
Nov 7, 2025
Maintains: Overweight
Price Target: $94 → $98
Current: $63.25
Upside: +54.94%
Aug 7, 2025
Maintains: Neutral
Price Target: $3.5 → $4
Current: $4.26
Upside: -6.10%
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $178.49
Upside: +17.65%
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.36
Upside: +83.82%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $10.55
Upside: +222.27%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $11.64
Upside: +37.46%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $74.86
Upside: +2.86%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $3.46
Upside: +30.06%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $219.97
Upside: +20.47%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $2.05
Upside: +192.68%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $0.71
Upside: +2,720.87%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $452.58
Upside: -17.80%